Latest Breaking News On - Yuanwei chen - Page 1 : comparemela.com

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). HP518 is currently in Phase I clinical trials in Australia. The open-label study approved by FDA will assess the safety, pharmacokinetics, and anti-tumor activity of HP518. "HP518 is a novel drug expected to address the unmet clinical needs of prostate cancer treatment," said Yuanwei Chen, Ph.D., President and CEO of Hinova. "The available study results of HP518 strengthen our confidence that HP518 is a potentially new treatment for drug resistant prostate cancer. We are

Yuanwei chenPrnewswire hinova pharmaceuticals incDrug administrationPharmaceuticals incFeb 7023 prnewswire hinova pharmaceuticals incA clinical stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseasesEcently announced that the us food and drug administration fda has cleared company 39s investigational new application ind for its innovative hp518N oral chimeric degrader targeting androgen receptor ar for the treatment of metastatic castration resistant prostate cancer mcrpc hp518 is currently in phasei clinical trials australia open label study approved by fda will assess safetyNd anti tumor activity of hp518 quot isa novel drug expected to address the unmet clinical needs prostate cancer treatmentUot said yuanwei chenResident and ceo of hinova quot the available study results hp518 strengthen our confidence that isa potentially new treatment for drug resistant prostate cancer we are making full efforts to advance clinicalOping hp518 will provide more clinical benefits to patients worldwide in the future quot has been discovered and developed through hinova 39s targeted protein degradation drug discovery platform it potential overcome resistance of prostate cancer that is due some specific ar mutations isa validated therapeutic target treat during treatmentRug resistance becomes inevitable due to multiple mechanismsNcluding ar amplification or mutationsTc in preclinical studies